Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Overview
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Companies Involved in Therapeutics Development
AbbVie Inc
Boehringer Ingelheim Intertiol GmbH
ConSynce Therapeutics Inc
Dart NeuroScience LLC
Disc Medicine Inc
Mental-Heal Ltd
Pfizer Inc
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Drug Profiles
bitopertin - Drug Profile
Product Description
Mechanism Of Action
History of Events
CSTI-200 - Drug Profile
Product Description
Mechanism Of Action
DNS-006 - Drug Profile
Product Description
Mechanism Of Action
iclepertin - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PGW-5 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit GlyT1 for Parkinson’s Disease and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Glyt1 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Glyt1 for Unspecified Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
VU-0410120 - Drug Profile
Product Description
Mechanism Of Action
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Dormant Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Discontinued Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Product Development Milestones
Featured News & Press Releases
Nov 03, 2022: Disc Medicine announces presentations on Bitopertin across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
Oct 31, 2022: Disc Medicine initiates AURORA, a phase 2 clinical study of Bitopertin in adults with Erythropoietic Protoporphyria (EPP)
Aug 10, 2022: Disc Medicine initiates BEACON, a phase 2 clinical study of Bitopertin in patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
Nov 11, 2021: Disc Medicine announces oral presentation on bitopertin at the 63rd American Society of Hematology Annual Meeting
May 24, 2021: Boehringer Ingelheim’s investigatiol treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Desigtion
Sep 15, 2020: Boehringer’s drug improves cognition in Phase II schizophrenia trial
Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
Dec 06, 2010: Phase II Study With First-In-Class Investigatiol Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia
Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by ConSynance Therapeutics Inc, 2022
Pipeline by Dart NeuroScience LLC, 2022
Pipeline by Disc Medicine Inc, 2022
Pipeline by Mental-Heal Ltd, 2022
Pipeline by Pfizer Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022